Enekinragene Inzadenovec for Knee Arthritis

This trial explores a new treatment, Enekinragene Inzadenovec (PCRX-201), for knee osteoarthritis, which can make walking and daily activities painful. Researchers aim to determine if a single injection of PCRX-201, administered at two different doses, is safe and can reduce knee pain while improving joint function. They seek individuals who have experienced knee osteoarthritis symptoms for over a year and have tried at least two other treatments without success. Participants will receive regular checkups to monitor progress over several years. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial does not specify if you need to stop taking your current medications, but you cannot have used certain knee injections or gene therapy recently. It's best to discuss your specific medications with the trial team.

Research has shown that enekinragene inzadenovec (PCRX-201) was safe in earlier studies. Participants who received a single injection of PCRX-201 generally tolerated it well, with no major safety issues identified. The data suggest that the treatment is safe, as it did not cause significant negative effects. This information comes from previous human trials where a single injection was administered in the knee.¹²³⁴⁵

Enekinragene Inzadenovec (PCRX-201) is unique because it offers a novel approach to treating knee arthritis through a single intra-articular injection that directly targets the affected area. Unlike current treatments such as NSAIDs, corticosteroids, or physical therapy, Enekinragene Inzadenovec works potentially by modulating specific genetic pathways linked to inflammation and cartilage health. This targeted mechanism could reduce side effects associated with systemic medications and provide more efficient relief. Researchers are excited about this treatment's potential to offer faster and more sustained relief from arthritis symptoms, improving the quality of life for patients.

Research has shown that enekinragene inzadenovec, also known as PCRX-201, may help treat knee osteoarthritis. Studies have found that a single injection can lead to lasting improvements in pain, stiffness, and joint function for up to three years. This trial will test different doses of PCRX-201, with some participants receiving Dose A and others receiving Dose B, to evaluate its effectiveness and safety. The treatment uses a special method to deliver helpful genes directly to the knee joint. Clinical data suggests that PCRX-201 is both effective and safe, offering a potential option for people with knee osteoarthritis. Results so far are promising, with patients experiencing significant relief and improved mobility.¹²⁶⁷⁸